Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

NCT06120491 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1800

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-Sensitive Prostate Cancer

Interventions

DRUG: Saruparib
DRUG: Placebo
DRUG: Abiraterone Acetate
DRUG: Darolutamide
DRUG: Enzalutamide

Sponsor

AstraZeneca